COMMUNIQUÉS West-GlobeNewswire

CB2 Insights Acquires Multi-Location Medical Cannabis Clinic Group, Relaxed Clarity
04/04/2019
Accretive acquisition of Colorado-based clinic group bolsters Company’s US medical cannabis clinical roll-up strategy; adds 15,000 new patients TORONTO, April 04, 2019 (GLOBE NEWSWIRE) -- CB2 Insights (“CB2” or the “ [...]
Paratek Pharmaceuticals Presenting New Data from NUZYRA™ (Omadacycline) Development Program at ECCMID 2019
04/04/2019
Data Highlight Paratek’s Commitment to Further Understanding Omadacycline’s Utility in Life-Threatening Infections such as CABP and ABSSSI BOSTON, April 04, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq [...]
SELLAS Life Sciences Group and World-Renowned Cancer Center to Study Galinpepimut-S (GPS) in Combination with Nivolumab in Patients with Malignant Pleural Mesothelioma (MPM)
04/04/2019
Initiation of Phase 1 Clinical Trial in Relapsed or Refractory MPM Expected in the Second Quarter of 2019 Previous Combination Study of GPS and Nivolumab Given After Salvage Chemotherapy in Ovarian Cancer Patients [...]
PSIQ Reports Record Breaking Annual Revenues of $ 876,448 for 2018 as Compared to $ 208,236 for 2017, an Increase of Over 400% and Poised for Rapid Expansion in 2019
04/04/2019
SUNRISE, Fla., April 04, 2019 (GLOBE NEWSWIRE) -- Profile Solutions, Inc. (OTC Pink: PSIQ) announced today that its wholly owned subsidiary, Elite Products International, Inc. (“Elite”), reported Revenues for the year [...]
Abeona Therapeutics Receives FDA Fast Track Designation for ABO-101 for Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
04/04/2019
Ongoing Phase 1/2 study of ABO-101 enrolling eligible patients with MPS IIIB NEW YORK and CLEVELAND, April 04, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene [...]
Gritstone Oncology Announces the Addition of Eugene Zhukovsky, Expert in Bispecific Biotherapeutics Development, to its Scientific Advisory Board
04/04/2019
EMERYVILLE, Calif., April 04, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer [...]
Aptinyx to Present at 18th Annual Needham Healthcare Conference
04/04/2019
EVANSTON, Ill., April 04, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, [...]
Entasis Therapeutics Initiates Global Phase 3 Pivotal Trial of ETX2514SUL for Patients with Carbapenem-Resistant Acinetobacter Infections
04/04/2019
WALTHAM, Mass., April 04, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company developing novel antibacterials to treat serious drug-resistant infections [...]
Final Results from The Heart EXPAND Pivotal Trial Using the Organ Care System (OCS) Heart Technology Presented at the 2019 Annual Meeting of The International Society for Heart and Lung Transplantation in Orlando
04/04/2019
ANDOVER, Mass., April 04, 2019 (GLOBE NEWSWIRE) -- TransMedics, Inc., a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, announced the [...]
Alpha Pro Tech, Ltd. Announces the Launch of Three New Products Expanding Building Supply Market Opportunity
04/04/2019
TECHNO SB® 25 & TECHNO SB® ULTRA Synthetic Roof Underlayment REXTREME Premium Window and Door Flashing Nogales, Ariz., April 04, 2019 (GLOBE NEWSWIRE) -- Alpha Pro Tech, Ltd. (NYSE American: APT) , a leading [...]
Samumed Doses First Subject in Phase 1 Trial of SM07883, a Potential Treatment for Alzheimer’s Disease
04/04/2019
DYRK1A Inhibition as a Potential Treatment for Alzheimer’s Disease Supported by Data Presented at International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2019) SAN DIEGO, April 04, 2019 (GLOBE NEWSWIRE [...]
Allan Oberman Appointed Chairman of Jay Pharma’s Board of Directors
04/04/2019
TORONTO, April 04, 2019 (GLOBE NEWSWIRE) -- Jay Pharma Inc., a company dedicated to developing innovative, evidence-based cannabinoid medicines to address unmet patient needs in cancer care, today announced the [...]
Progressive Care Inc. Officially Moves to Newly Purchased Building
04/04/2019
MIAMI, April 04, 2019 (GLOBE NEWSWIRE) -- Progressive Care Inc. ( OTCQB: RXMD ) (“Progressive Care” or the “Company”), a personalized healthcare services and technology company, announced today that it will be moving [...]
Tower One Secures Financing for 150 Towers
04/04/2019
VANCOUVER, British Columbia, April 04, 2019 (GLOBE NEWSWIRE) -- TOWER ONE WIRELESS CORP. (CSE: TO) (OTCQB: TOWTF) (Frankfurt: 1P3N) (“Tower One” or the “Company”) announced today it has entered into a development [...]
IntelGenx Presents at 14th International Conference on Alzheimer’s and Parkinson’s Disease
04/04/2019
SAINT LAURENT, Quebec, April 04, 2019 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced its two Montelukast poster presentations received [...]
Blueberries Medical Commences Formal Development Process for the Cultivation of Cannabis in Jujuy Argentina
04/04/2019
TORONTO, April 04, 2019 (GLOBE NEWSWIRE) -- Blueberries Medical Corp. (CSE: BBM) (OTCQB: BBRRF) (FRA: 1OA) (the “ Company ” or " Blueberries "), a Latin American focused licensed producer of medicinal cannabis and [...]
ISRACANN Biosciences: Invest in Israel’s First Cannabis Pure-Play Public Offering -- CFN Media
04/04/2019
Seattle, Washington, April 04, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces [...]
Joseph J. Galligan Appointed as Senior Advisor to BioCorRx Inc.
04/04/2019
ANAHEIM, CA, April 04, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a leader, developer and provider of advanced solutions in the treatment of addiction and related [...]
Tonix Pharmaceuticals Plans to Expand TNX-102 SL Phase 3 Program Beyond PTSD to Include Fibromyalgia
04/04/2019
Encouraging FDA Meeting Minutes Support Phase 3 Development of TNX-102 SL 5.6 mg in Fibromyalgia NEW YORK, April 04, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a [...]

Pages